Table 2 APR-246 used in clinical trial among subjects suffering from some malignancies; Tables and data are adopted from clinicaltrials.gov. (https://clinicaltrials.gov/)
Status of trial | Conditions (Title) | Interventions of clinical trial | Study type | Study completion time |
|---|---|---|---|---|
Not yet recruiting New | • Treatment of TP53 mutant myelodysplastic Syndromes (MDS) | • Drug: APR-246 + azacitidine and Azacitidine | Interventional, phase 3 | 2020 |
Recruiting | • Esophageal carcinoma | • Drug: APR-246 | Interventional, phases 1 and 2 | 2023 |
Recruiting | • Myelodysplastic syndrome with gene mutation • Acute myeloid leukemia with gene mutations • Myeloproliferative neoplasm • Chronic myelomonocytic Leukemia | • Drug: APR-246 and Azacitidine • Combination therapy with APR-246 and Azacitidine | Interventional, phases 1 and 2 | 2021 |
Recruiting | • myeloid neoplasms with TP53 mutant • Acute myeloid leukemia • Chronic myelomonocytic leukemia | • Drug: APR-246 and Azacitidine | Interventional, phases 1 and 2 | 2021 |
Active | • BRAF V600 mutant melanoma | • Drug: APR-246 and Dabrafenib | Interventional, phases 1 and 2 | 2018 |
Active | • P53 activation in platinum resistant serous advanced OC | • Drug: APR-246 and pegylated liposomal doxorubicin hydrochloride (PLD) | Interventional, phase 2 | 2019 |
Completed | • Prostate cancer or refractory hematologic cancer | • Drug: APR-246 | Interventional, phase 1 | 2010 |
Active | • Platinum sensitive recurrent advanced serous OC (mutated p53) | • Drug: APR-246 and Carboplatin and PLD | Interventional, phases 1 and 2 | – |